CA-ARIBIO-CO.,-LTD.
31.3.2023 18:01:37 CEST | Business Wire | Press release
AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer’s disease who were treated with 10mg and 30mg of AR1001. AR1001 is a potent PDE5 inhibitor with preliminary efficacy in cognition, and preclinical effects on neuron apoptosis inhibition, promotion of neurogenesis, increase in neuroplasticity, and stimulation of autophagy to remove toxic proteins.
The phase 2 study was a double-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and preliminary efficacy of AR1001 over 26 and 52 weeks of treatment in patients with mild to moderate Alzheimer’s disease. The trial enrolled 210 patients at 21 research centers in the United States.
Plasma collected from patients at baseline, week 26 and week 52 was analyzed by Quantarix using the Simoa HD-X analyzer. Meaningful, statistically significant changes were found over 52 weeks of treatment in a post-hoc analysis, including a dose dependent decline of pTau181 at 26 weeks, and further declines after 52 weeks of treatment. Patients randomized to 10 and 30 mg AR1001 treatment after 26 weeks of treatment with placebo also demonstrated similar declines in pTau181. Other plasma markers including NfL, GFAP and AB42/40 ratio were also measured but showed minimal change or no statistical differences over baseline levels.
AriBio initiated a phase 3 pivotal trial with 30mg of AR1001 to be administered daily to early and mild Alzheimer’s disease patients in December of 2022. Enrollment is expected to continue through 2024. “This biomarker data helps bolster the positive effects seen in cognition with the high dose of AR1001 in the Phase 2 study in mild AD patients. We will continue to collect both CSF and plasma as part of the phase 3 study to analyze as supportive data,” stated Dr. Greeley.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is a Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005009/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MTN Group Fintech Advances Digital Transformation Through Strategic Technology Partnership11.6.2026 04:00:00 CEST | Press release
MTN Group Fintech has entered into a strategic partnership with Ant International, a leading global digital payment, digitisation and financial technology provider, to accelerate the transformation of its mobile money ecosystem. The partnership, which is expected to launch in Nigeria next quarter, will introduce a super-app platform designed to enhance user experience, deepen digital inclusion and enable a next-generation ecosystem for digital finance, lifestyle and commerce services around MoMo. By leveraging Ant International’s advanced technology, MTN is evolving MoMo to enable stronger ecosystem integration through a mini app platform, enhanced fraud prevention and richer engagement features for consumers and merchants. The partnership represents a major step in building a more resilient and future-ready digital ecosystem. “This partnership aligns with MTN Group’s ambition of leading digital solutions for Africa’s progress by leveraging scale, technology and strong global partnersh
Andersen Global styrker sine globale mobilitetskompetencer med tilføjelsen af Courdid BV10.6.2026 22:05:00 CEST | Pressemeddelelse
Andersen Global har indgået en samarbejdsaftale med Courdid BV, som er et hollandsk konsulentfirma inden for global mobilitet, hvilket yderligere styrker organisationens rådgivningskapacitet for internationale arbejdsstyrker og expats. Courdid BV blev grundlagt for næsten to årtier siden og tilbyder en bred vifte af rådgivningstjenester inden for lønsums- og lønskat, expatbeskatning, lønudbetaling, immigration samt employer of record-løsninger. Virksomheden samarbejder med multinationale arbejdsgivere, offentlige institutioner og professionelle serviceudbydere om at levere praktisk og skræddersyet rådgivning om komplekse internationale arbejdsstyrkeforhold – kendetegnet ved en kundeorienteret tilgang, der prioriterer tilgængelighed og personlig service. "Vi bestræber os på at være praktiske og relevante for vores klienter, særligt inden for områder, der ofte er unødigt komplekse," siger Jean-Paul van ’t Hof, der er administrerende partner i Courdid BV. "Ved at blive en samarbejdende vi
TestMu AI Announces Day-Zero Support for macOS Golden Gate and iOS 27 Beta Following WWDC 202610.6.2026 21:52:00 CEST | Press release
Developers can now test websites, web applications, and mobile apps on Apple's latest operating systems before their public release TestMu AI (formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, today announced day-zero support for Apple's newly unveiled operating systems, macOS Golden Gate and iOS 27 Beta, across its cloud testing platform. Announced at Apple's Worldwide Developers Conference (WWDC) 2026, macOS Golden Gate and iOS 27 introduce significant platform updates that will impact application compatibility, user experience, and performance. Both operating systems are now available for testing on TestMu AI, the same day Apple released its beta versions, allowing engineering teams to identify issues months before the stable rollout reaches millions of users worldwide. macOS Golden Gate is available through the TestMu AI Real Time Testing platform, while iOS 27 Beta is available on TestMu AI Real Device Cloud across the latest iPhones and i
Pure Lithium Corporation Named World Economic Forum Technology Pioneer10.6.2026 20:10:00 CEST | Press release
Lithium metal battery innovator joins a select global cohort of 100 pioneering companies shaping the future of energy and advanced materials Pure Lithium Corporation, a disruptive lithium metal battery technology company, is pleased to announce that the company has been selected as a 2026 Technology Pioneer by the World Economic Forum. Launched in 2000, the Technology Pioneers is a leading community for companies from around the world that are shaping the future through breakthrough technologies and innovations. These companies are selected for their potential to have a significant impact on business and society and are invited to engage with public and private sector leaders through the World Economic Forum’s global platform. “We are delighted to be selected as a World Economic Forum Technology Pioneer. I would like to express my gratitude to the World Economic Forum for this honor,” said Pure Lithium Founder, Chairman and CEO, Emilie Bodoin. “Pure Lithium’s selection is a testament t
Visa Partners with OpenAI to Power the Next Generation of AI Commerce10.6.2026 20:00:00 CEST | Press release
New collaboration brings Visa’s global payment networkto one of the largest AI platforms and aims to support seamless, secure transactions and broader AI-powered use cases across commerce environments supported by agents Visa (NYSE: V) today announced a strategic collaboration with OpenAI to enable secure Visa payments within agentic commerce, enabling seamless and trusted payments across OpenAI. The companies made the announcement at the Visa Payments Forum in San Francisco. Through the partnership, Visa will provide its global network, credentialing capabilities and security infrastructure to support agentic commerce experiences, helping consumers and businesses interact and transact with confidence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610422687/en/ The collaboration is part of the broader Visa Intelligent Commerce initiative, which is focused on extending secure payment capabilities into new digital environm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom